Uniformed Services University of the Health Sciences
Department of Preventive Medicine and Biometrics
4301 Jones Bridge Road
Bethesda, Maryland 20814-4799
Bldg. A, Room A1044
Phone: (301) 295-3173
Professor and Chair of Preventive Medicine and Biometrics
Retired career as Public Health Service Officer with background in regulation and public policy regarding vaccines and others biological products. On faculty of USUHS, Department of Preventive Medicine and Biometrics since 1993, Chair of Department since 2002.
Preponderance of research since joining faculty at USUHS has been focused on development of a vaccine against Human Immunodeficiency Virus
Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S, Flora MN, and Quinnan GV. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of an HIV-1 envelope associated with a broadly cross-reactive, primary virus neutralizing antibody response. 2002. J. Virol. 76: 644-55.
Dong M, Zhang PF, Grieder F, Lee J, Krishnamurthy G, VanCott T, Broder C, Yu X-F, Shao Y, Faix C, Valente P, and Quinnan GV. Induction of primary virus cross-reactive human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies in small animals using an alphavirus derived in vivo expression system. J Virol 2003, 77: 3119-3130.
Leavitt M, Park E, Dimitrov D, and Quinnan GV. A region on the inner domain of HIV-1 gp120 interacts functionally with the gp41 leucine zipper domain to determine responsiveness to CD4 and infectivity: a potential gp41-binding site. J Virol 2003, 77: 560-70.
Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV Jr, Parren PW, Burton DR. A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12. J Virol. 2003; 77: 6965-6978.
Bouma P, Leavitt M, Zhang PF, Sidorov I, Dimitrov D, Quinnan G. Multiple Interactions Across the Surface of the gp120 Core Structure Determine the Global Neutralization Resistance Phenotype of HIV-1. J Virol. 2003, 77: 8061-71.
Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol. 2004 Sep;78(17):9233-42.
Zhang M-Y, Shu Y, Cham F, Bouma P, Quinnan GV, and Dimitrov DS. Identification and Characterization of a New Cross-Reactive Human Immunodefficiency Virus Type 1 Neutralizing Human Monoclonal Antibody. J Immunol Meth 2003; 283: 17-25.
Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng Y-R, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T and Dimitrov DS. Broadly Cross-Reactive HIV Neutralizing Human Monoclonal Antibody Fab Selected by Sequential Antigen Panning of a Phage Display Library. J Immunol Methods 2003, 283: 17-25.
Santos PD, Achee NL, Quinnan GV, and Roberts DR. Use of polymerase chain reaction technique to confirm VecTest screening results in Plasmodium falciparum and P. vivax VK210 laboratory infected Anopheles stephensi mosquitoes. J Amer Mosquito Control Assoc. 2004; 20:265-271.
Quinnan GV, Yu XF, Lewis MG,Zhang PF, Sutter G, Silvera P, Dong M, Choudhary A, Sarkis PTN, Bouma P, Zhang Z, Montefiori DC, VanCott TC, Broder TC. Protection of Rhesus Monkeys Against Infection with Minimally Pathogenic, Simian-Human Immunodeficiency Virus: Correlations with Neutralizing Antibodies and Cytotoxic T Cells. J Virol, 2005; 79, 3358-3369.
Alarcon JO, Friedman HB, Montano SM, Zunt JR, Holmes KK, Quinnan GV Jr. High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in Peru. J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):604-9.
Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, Robinson J, van der Groen G, Quinnan GV Jr. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology. 2006 Mar 30; 347(1):36-51.
Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, Zhang Z, Shao Y, Feng YR, Wang L, Mathy N, Voss G, Broder CC, and Quinnan GV. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. PNAS 104: 10193-8, 2007.
Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV Jr, Dimitrov DS. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363: 79-90, 2007.
Santos-Ciminera PD, Alecrim MGC, Manso MFC, Roberts DR, and Quinnan GV. Malaria in the State of Amazonas and Funda??o De Medicina Tropical Do Amazonas, Brazil. Emerging Infectious Diseases 13: 1597-1600, 2007.
Santos-Ciminera PD, Roberts DR, Alecrim MGC, and Quinnan GV. Molecular epidemiology of Plasmodium vivax in the State of Amazonas, Brazil. Acta Trop 102: 38-46, 2007.
Zhang MY, Vu BK, Choudhary A, Lu H, Humbert M, Ong H, Alam M, Ruprecht R, Quinnan G, Jiang S, Montefiori D , Mascola JR, Broder CC, Haynes BF, and Dimitrov DS. Cross-Reactive Human Immunodeficiency Virus Type 1- Neutralizing Human Monoclonal Antibody which Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self Antigens. J. Virol. 82: 6869-79, 2008.
Chen W, Zhu Z, Liao H, Quinnan G, Broder CC, Haynes BF, and Dimitrov DS. Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. Viruses 2010, 2, 547-565.